文献速递临床微生物临床免疫

韩国某三级医院梭杆菌感染患者的临床差异及分离株抗菌药物敏感性

Clinical Differences in Patients Infected with Fusobacterium and Antimicrobial Susceptibility of Fusobacterium Isolates Recovered at a Tertiary-Care Hospital in Korea.
PubMed 文献 · Ann Lab Med · 2022-01-01

该研究回顾性收集2003—2020年韩国某三级医院86例梭杆菌感染患者的临床资料,并按CLSI指南用琼脂稀释法对76株非重复梭杆菌分离株做药敏试验。结果显示具核梭杆菌多见于血培养并与血液恶性肿瘤相关,坏死梭杆菌多见于头颈部感染;不同菌种感染患者死亡率无显著差异,但部分菌种对克林霉素、莫西沙星、青霉素G或头孢曲松耐药。

要点

  • 具核梭杆菌多分离自血培养,且与血液恶性肿瘤相关。
  • 坏死梭杆菌主要见于头颈部感染。
  • 不同梭杆菌感染患者死亡率无显著差异。

核心结论

  • 临床重要梭杆菌感染患者虽存在临床差异,但死亡率无显著差异。
  • 部分梭杆菌菌种对青霉素G、头孢曲松、克林霉素或莫西沙星耐药。
  • 该研究可为梭杆菌感染的 empirical 治疗提供临床相关数据。

研究设计与样本

  • 回顾性研究,收集2003—2020年韩国某三级医院86例梭杆菌感染患者的临床资料。
  • 选取76株非重复梭杆菌分离株,按CLSI指南(M11-A9)用琼脂稀释法进行药敏试验。

主要发现

  • 具核梭杆菌最常分离自血培养,并与血液恶性肿瘤相关。
  • 坏死梭杆菌主要见于头颈部感染。
  • 抗厌氧菌药物更常用于治疗具核梭杆菌和可变梭杆菌感染,而非坏死梭杆菌感染。
  • 不同菌种感染患者死亡率无显著差异。
  • 所有具核梭杆菌和坏死梭杆菌分离株对所测抗菌药物均敏感。

关键数值与推荐

  • 可变梭杆菌对克林霉素耐药率为48%,对莫西沙星耐药率为24%。
  • 死亡梭杆菌对青霉素G耐药率为22%,对头孢曲松耐药率为67%。
  • 未检测到β-内酰胺酶活性。

临床怎么用

  • 针对梭杆菌感染的经验性治疗需考虑菌种间耐药差异。
  • 对可变梭杆菌和死亡梭杆菌感染,不宜盲目依赖克林霉素、莫西沙星、青霉素G或头孢曲松。
  • 临床微生物实验室应重视梭杆菌的菌种鉴定与药敏试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fusobacterium species are obligately anaerobic, gram-negative bacilli. Especially, F. nucleatum and F. necrophorum are highly relevant human pathogens. We investigated clinical differences in patients infected with Fusobacterium spp. and determined the antimicrobial susceptibility of Fusobacterium isolates. METHODS: We collected clinical data of 86 patients from whom Fusobacterium spp. were isolated from clinical specimens at a tertiary-care hospital in Korea between 2003 and 2020. In total, 76 non-duplicated Fusobacterium isolates were selected for antimicrobial susceptibility testing by the agar dilution method, according to the Clinical and Laboratory Standards Institute guidelines (M11-A9). RESULTS: F. nucleatum was most frequently isolated from blood cultures and was associated with hematologic malignancy, whereas F. necrophorum was mostly prevalent in head and neck infections. Anti-anaerobic agents were more commonly used to treat F. nucleatum and F. varium infections than to treat F. necrophorum infections. We observed no significant difference in mortality between patients infected with these species. All F. nucleatum and F. necrophorum isolates were susceptible to the antimicrobial agents tested. F. varium was resistant to clindamycin (48%) and moxifloxacin (24%), and F. mortiferum was resistant to penicillin G (22%) and ceftriaxone (67%). β-Lactamase activity was not detected. CONCLUSIONS: Despite the clinical differences among patients with clinically important Fusobacterium infections, there was no significant difference in the mortality rates. Some Fusobacterium spp. were resistant to penicillin G, ceftriaxone, clindamycin, or moxifloxacin. This study may provide clinically relevant data for implementing empirical treatment against Fusobacterium infections.

来源:Ann Lab Med,查看原文。版权归原作者所有。

引用

  1. Kim M, Yun SY, Lee Y, et al. Clinical Differences in Patients Infected with Fusobacterium and Antimicrobial Susceptibility of Fusobacterium Isolates Recovered at a Tertiary-Care Hospital in Korea. Ann Lab Med. 2022. PMID: 34635612. doi:10.3343/alm.2022.42.2.188

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。